MIRA
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- MIRA Pharmaceuticals advanced Ketamir-2 into Phase 2a for chemotherapy-induced peripheral neuropathy following FDA reviewSep 17, 2026
- MIRA Pharmaceuticals submitted a Phase 2a trial protocol to the FDA for Ketamir-2 in chemotherapy-induced peripheral neuropathyJun 17, 2026
- MIRA Pharmaceuticals reported positive unblinded Phase 1 data for Ketamir-2May 14, 2026
- MIRA Pharmaceuticals announced acceptance of a peer-reviewed manuscript for its oral obesity and nicotine addiction drug candidateMay 13, 2026
- MIRA Pharmaceuticals initiates multiple ascending dose Phase 1 study of oral Ketamir-2 and selects chemotherapy-induced neuropathic pain as lead Phase 2a indicationOct 24, 2025